X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs MYLAN (US) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   MYLAN
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
MYLAN
Dec-14
PANACEA BIOTECH/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1494,053-   
Low Rs822,856-   
Sales per share (Unadj.) Rs84.11,387.6-  
Earnings per share (Unadj.) Rs-18.3167.2-  
Cash flow per share (Unadj.) Rs-6.7269.1-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7689.8-  
Shares outstanding (eoy) m61.25378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.42.5 55.1%   
Avg P/E ratio x-6.320.7 -30.5%  
P/CF ratio (eoy) x-17.212.8 -134.3%  
Price / Book Value ratio x1.45.0 27.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,307,233 0.5%   
No. of employees `0002.825.0 11.0%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.121,001.5 8.9%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.72,530.0 -16.1%   
INCOME DATA
Net Sales Rs m5,154525,037 1.0%  
Other income Rs m100-3,060 -3.3%   
Total revenues Rs m5,254521,977 1.0%   
Gross profit Rs m-766130,579 -0.6%  
Depreciation Rs m71138,562 1.8%   
Interest Rs m1,50322,647 6.6%   
Profit before tax Rs m-2,88166,310 -4.3%   
Minority Interest Rs m11-272 -4.0%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m172,788 0.6%   
Profit after tax Rs m-1,12163,249 -1.8%  
Gross profit margin %-14.924.9 -59.8%  
Effective tax rate %-0.64.2 -13.9%   
Net profit margin %-21.812.0 -180.6%  
BALANCE SHEET DATA
Current assets Rs m3,810461,577 0.8%   
Current liabilities Rs m8,365360,861 2.3%   
Net working cap to sales %-88.419.2 -460.8%  
Current ratio x0.51.3 35.6%  
Inventory Days Days15678 199.4%  
Debtors Days Days67107 62.7%  
Net fixed assets Rs m14,480121,466 11.9%   
Share capital Rs m6118,567 0.3%   
"Free" reserves Rs m9030-   
Net worth Rs m5,127260,995 2.0%   
Long term debt Rs m5,832389,901 1.5%   
Total assets Rs m19,4331,051,265 1.8%  
Interest coverage x-0.93.9 -23.3%   
Debt to equity ratio x1.11.5 76.1%  
Sales to assets ratio x0.30.5 53.1%   
Return on assets %2.08.2 24.0%  
Return on equity %-21.924.2 -90.2%  
Return on capital %3.613.6 26.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m59969,017 0.9%  
From Investments Rs m-438-54,428 0.8%  
From Financial Activity Rs m-303-18,186 1.7%  
Net Cashflow Rs m-141-3,598 3.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare PANACEA BIOTECH With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: CIPLA  AJANTA PHARMA  SUVEN LIFE  AUROBINDO PHARMA  FDC LTD.  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 19, 2018 03:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS